Abstract. Cancer cells can fuse spontaneously with normal host cells, including endothelial cells, and such fusions may strongly modulate the biological behaviour of tumors. However, the underlying mechanisms are unknown. We now show that human breast cancer cell lines and 63 out of 165 (38%) breast cancer specimens express syncytin, an endogenous retroviral envelope protein, previously implicated in fusions between placental trophoblast cells. Additionally, endothelial and cancer cells are shown to express ASCT-2, a receptor for syncytin. Syncytin antisense treatment decreases syncytin expression and inhibits fusions between breast cancer cells and endothelial cells. Moreover, a syncytin inhibitory peptide also inhibits fusions between cancer and endothelial cells. These results are the first to show that syncytin is expressed by human cancer cells and is involved in cancer-endothelial cell fusions.
A number of cell fusions occur during normal development. These include the fusion between the sperm and the egg cell and continue with fusions between placental trophoblasts to form syncytiotrophoblasts, between myoblasts to form muscle fibres and between macrophages to form osteoclasts [1] . Recently, the human endogenous retroviral envelope protein syncytin (env-W) was shown to be involved in fusions between placental trophoblasts [2, 3] . Such fusions result in the formation of syncytiotrophoblasts and involve the expression of a syncytin receptor, the neutral amino acid transporter ASCT-2, also referred to as the D-type retroviral receptor [2] . Although many endogenous retroviral sequences have degenerated during evolution, the syncytin sequence appears to have been conserved due to its ability to contribute to reproductive functions. Several studies have shown that cancer cells may spontaneously fuse with normal host cells in vitro [4] [5] [6] [7] [8] [9] and in vivo [5, [10] [11] [12] [13] . Such fusions result in cell hybrids containing an admixture of the parental genomes [5, 11] . In hybrids formed from fusions induced to occur between cancer and normal cells, tumorogenicity is usually suppressed [14] [15] [16] [17] [18] , due to activation of tumour suppressor genes contributed by the normal fusion partner [reviewed in 18] . However, in some cases, for example the formation of hybridomas producing monoclonal antibodies, tumorogenicity is not suppressed [19; for overviews see refs. 4, 20, 21] . Moreover, tumour suppression has been shown to be absent in hybrids formed from cells with a dominant negative mutation in p53 or expressing specific oncogenes [22] . The mechanisms by which cancer cells can spontaneously fuse with host cells are currently not understood, but are important, since such fusions modify the biological behavior of the ensuing hybrids. Moreover, the possible occurrence of spontaneous fusions betweeen cancer cells themselves [8] may contribute to aneuploidy and altered biological behaviour. Previously, we reported that human breast cancer cells are able to fuse spontaneously with endothelial cells to form hybrid cells expressing protein and chromosomal markers characteristic of both parent cell lines [5] . Initially, heterokaryons appeared but, subsequently, mitotic figures and synkaryons, containing an admixture of the parental genomes in a single nucleus were observed [5] . In addition, studies in nude mice revealed that intravenous injection of metastasizing breast cancer (MDA-MB-231) cells resulted in the formation of hybrid cells containing both human and mouse chromosomes and showing endothelial cell characteristics [5] . Recent data suggest that similar fusions may also occur in humans [reviewed in refs. 4, 20 and 21] . We now demonstrate that the fusogenic protein syncytin is expressed in breast cancers and in breast cancer cell lines and also show that endothelial cells, as well as cancer cells, express the syncytin receptor ASCT-2. Moreover, antisense-mediated downregulation of syncytin expression, as well as a syncytin inhibitory peptide, inhibits fusions between breast cancer cells and endothelial cells. This demonstrates that the requirements for cancer-endothelial cell fusions are present in many cases of human breast cancer and provides direct proof that syncytin is involved in such fusions.
Materials and methods
Cell culture. Breast cancer cells (MCF-7, MDA-MB-231), human umbilical vein endothelial cells (HUVECs) and calf pulmonary artery endothelial (CPAE) cells were cultured as described previously [5, 23] . MCF-7 cells were transfected with a previously characterized [24] phosphorthioate-protected syncytin antisense oligonucleotide (env-W 758-777) or with a scrambled control oligonucleotide [24] using oligofectamine (Invitrogen, Carlsbad, Calif.). After 48 h, MCF-7 cells were either extracted for protein and RNA or were trypsinized, allowed to recover for 1 h and then co-cultured for 24 h with HUVECs or CPAE cells in chamber slides (Nalge Nunc, Naperville, Ill.). Additionally, MCF-7 cells were co-cultured with HUVECs for 24 h in the presence of 5 μg/ml of a synthetic syncytin peptide (Ross-Petersen, Hørsholm, Denmark), previously shown to inhibit syncytin-mediated fusions [25] . Control cells were incubated with equivalent concentrations of a control peptide (Cpeptide(3-33); Sigma, St. Louis, Mo.) as well as without any peptide. Cells were fixed in 3.7% paraformaldehyde in phosphate-buffered saline and permeabilized in 0.1% Triton X-100 or were left unpermeabilized.
Immunocytochemistry and cell fusion assays. Tumours from 165 female patients with ductal breast cancers without axillary lymph node involvement were fixed in 10% buffered formalin and embedded in paraffin. Deparaffinized sections underwent antigen retrieval by microwaving and were stained with rabbit antisera to the extracellular domain of syncytin (pab-10109; Orbigen, San Diego, Calif.) or to ASCT-2 (Chemicon, Temecula, Calif.). The site of antigen-antibody reaction was revealed by biotinlabelled anti-rabbit IgG followed by peroxidase-labelled streptavidin (Dako, Glostrup, Denmark) and development in diaminobenzidine. Nuclei were counterstained with haematoxylin. Controls included use of antisera preabsorbed with the immunizing peptide (syncytin peptide was custom synthesized by Ross-Petersen and the ASCT-2 peptide was purchased from Chemicon). To determine whether endothelial cells contain the syncytin receptor, double immunofluorescence was carried out with monoclonal antibodies to an endothelial marker (CD31; Dako) in combination with rabbit anti-ASCT-2 antibodies, using detection with species-specific antibodies labelled with Alexa-594 or Alexa-488 (Molecular Probes, Eugene, Ore.), respectively. Live MCF-7 cells and MCF-7 cells fixed without permeabilization were stained with the syncytin antiserum followed by Alexa-488-labelled antirabbit IgG (Molecular Probes). For quantitation of cell fusions, co-cultured MCF-7 and endothelial cells were stained for double immunofluorescence using monoclonal antibodies recognizing the endothelial marker vimentin (3B4, IgG2a) and the epithelial marker cytokeratin (pancytokeratin; IgG1) (Dako) followed by subclass-specific second antibodies labelled with Alexa-488 (anti-IgG2a) or Alexa-594 (anti-IgG1) (Molecular Probes) [5] . Nuclei were stained with bisbenzimide (Hoechst 33258; Sigma). Controls, including use of type-matched monoclonal antibodies, as well as conventional staining controls were negative. Fused cells (cytokeratin and vimentin doublepositive cells) were counted in blind-coded specimens and results were expressed as a percentage of fused versus unfused cells. In each experiment, between 8 and 13 coded samples of each kind were counted and each experiment was repeated at least twice. The Mann-Whitney U test was used for statistical comparisons.
SDS-PAGE and immunoblotting.
Extraction, SDS-PAGE and electroblotting were performed as described elsewhere [26] . Antibodies to syncytin (Orbigen) and to HER-2 (Pharmingen, BD Biosciences, Heidelberg, Germany) were used in combination with chemiluminescent detection, and the intensities of the bands were quantitated using NIH Image software [26] . Syncytin protein levels were expressed relative to HER-2 protein levels.
RT-PCR.
Total RNA was prepared using the Trizol reagent. Reverse transcription employed the Superscript II kit (Life Technologies) following the manufacturer's recommendation for random hexamer RT and PCR, except that 2.5 units of AmpliTaq polymerase were used. Forty cycles of PCR, (annealing temperature 57 °C, 1.5 mM MgCl 2 ) were used. For detection of syncytin transcripts, primer A (CCGCTGAAAGAGGGGGAA) was used as upstream primer and primer B (TAGAG-GTTGTGCAGCTGAGA) was used as downstream primer [27] , producing an amplicon of 400 base pairs while bovine ASCT-2 was amplified using primer C (TGCTGACACCTGTGAGAAGG) as upstream primer and primer D (CACAGCCACAGCCACTAAAA) as downstream primer, producing an amplicon of 491 base pairs. Human ASCT-2 was amplified using primer E (GACCGTACGGAGTCGAGAAG) as upstream primer and primer F (GGGACGCAGCAGAACATTAT) as downstream primer, producing an amplicon of 445 base pairs. PCR products were size fractionated by agarose gel electrophoresis. Controls for lack of genomic contamination included omission of RT from the reaction as well as the use of intron-spanning primers detecting Hras (primer G: CCAGCTGATCCAGAACCATT and primer H: AGCCAGGTCACACTTGTTCC), producing an amplicon of 301 base pairs from cDNA and of 702 base pairs from genomic DNA. PCR products were sequenced by DNA Technology (Aarhus, Denmark).
Real-time RT-PCR. Levels of syncytin mRNA in MCF-7 cells treated with antisense or scrambled oligonucleotides were quantitated using real-time RT-PCR. PCR was performed on a LightCycler (Roche, Basel, Switzerland) using the SYBR green I Fast start kit (Roche) as described previously [26] , with primers A and B for syncytin and primers for HER-2 [26] . Syncytin mRNA levels were expressed relative to HER-2 mRNA levels.
Results

Syncytin is expressed by breast cancer cells and ASCT-2 is expressed by both cancer and endothelial cells.
RT-PCR of RNA isolated from MCF-7 and MDA-MB-231 breast cancer cells revealed amplicons of the expected size (400 base pairs) from both cancer cell lines (Fig. 1a) . No amplicon was obtained from endothelial cells. Exclusion of reverse transcriptase and use of intron-spanning primers documented lack of genomic contamination. Sequencing of the RT-PCR products revealed 99% (MCF-7) and 82% (MDA-MB-231) homology to syncytin. Immunoblotting using an antiserum against the extracellular domain of syncytin revealed a 62-kDa immunoreactive band in extracts of MCF-7 and MDA-MB-231 cells (Fig. 1b) , corresponding in size to a syncytin component present in the placenta [27] . Immunofluorescence staining of non-permeabilized MCF-7 cells showed that syncytin immunoreactivity was exposed on the external cell surface (Fig. 1c) . Immunocytochemistry showed that 63 out of 165 human breast cancer specimens (38%) contained cancer cells that reacted for syncytin (Fig. 2a) . A variable number of cancer cells were stained in individual tumors. Preabsorption (Fig. 2b) . Double immunofluorescence staining demonstrated expression of the syncytin receptor ASCT-2 in endothelial cells as well as in cancer cells (Fig. 2c) . Absorption of the antiserum with the immunizing peptide eliminated staining. RT-PCR of RNA extracted from human endothelial (HUVECs) and breast cancer (MCF-7, MDA-MB-231) cells revealed an amplicon of the size expected from human ASCT-2 mRNA (445 base pairs; data not shown). Additionally, RT-PCR of RNA from bovine endothelial (CPAE) cells demonstrated an amplicon of the size expected (491 base pairs) from bovine ASCT-2 mRNA (Fig. 1a) .
Antisense downmodulation of syncytin expression inhibits fusions between breast cancer cells and endothelial cells. Treatment of MCF-7 cells with a phosphorthioate-protected syncytin antisense oligonucleotide decreased syncytin mRNA levels (by 33.8 ± 5.0% compared with a control, scrambled phosphorthioate oligo) and protein levels (by 38.2 ± 13.2%). Levels were expressed relative to control mRNA/protein (HER-2) and therefore reflected a specific effect on syncytin expression. Transfected cells were co-cultured with HUVECs or with CPAE cells for 24 h and were then assayed for the frequency of cancer-endothelial cell fusion [5] . Briefly, co-cultures were fixed and triple-stained for vimentin (which is always expressed by HUVECs and by CPAE cells, but never by MCF-7 cells), cytokeratin (which is always expressed by MCF-7 cells, but never by HUVECs or CPAE cells) and DNA. After 24 h of co-culture, fused cells expressing both vimentin and cytokeratin and containing two or more nuclei were regularly observed in control co-cultures (Fig. 3a) . Such cells were never observed when MCF-7, HUVECs or CPAE cells were cultured alone. Quantitations of the frequency of fused cells in blind-coded specimens documented that antisense treatment significantly (p < 0.001) inhibited cancer-endothelial cell fusions (Fig. 3b ).
An inhibitory syncytin peptide inhibits fusions between breast cancer cells and endothelial cells. The previous results indicated that downmodulation of syncytin expression by an antisense oligonucleotide, which previously has been evaluated in placental cells [25] , inhibited fusions between MCF-7 cells. However, since it is not always possible to conclude from antisense experiments that the effect observed reflects a direct action of the molecule targeted, we also examined effects of a syncytin peptide sequence, which previously has been shown to inhibit syncytin-mediated fusions [24] . MCF-7 cells, co-cultured with HUVECs in the presence of this peptide, showed a highly significant (p < 0.001) reduction in the number of cell fusions compared with control cells that were exposed to equivalent concentrations of a control peptide (C-peptide) or were left untreated (Fig. 3) . There was no difference in the number of fusions between cells grown in the presence or absence of C-peptide (p = 0.6). Together, these results provide strong evidence that syncytin is directly involved in breast cancer-endothelial cell fusions.
Discussion
These data are the first to show that syncytin is expressed by human cancer cells. Thus, two human breast cancer cell lines and over a third of human ductal breast cancers were found to express syncytin. Previously, studies have demonstrated that syncytin is expressed in the placenta, testicles [2, 3] and brain [28] . For syncytin to induce cell fusions, fusion partners must express an appropriate receptor such as the D-type retroviral receptor, ASCT-2 [2]. We therefore examined breast cancers and cultured endothelial cells for expression of ASCT-2 and detected expression in both cell types in vitro and in vivo. These results show that the molecular requirements for syncytin-ASCT-2-mediated fusions are present in a significant number of breast cancer patients. Previously, we have documented that human breast cancer cells fuse with endothelial cells in a system validated by chromosomal and protein markers [5] . We therefore used this system to test whether syncytin was involved in mediating cancerendothelial cell fusions. Syncytin expression was downmodulated by an antisense oligonucleotide sequence, which has been previously shown to specifically decrease syncytin expression and to inhibit fusions between placental trophoblasts [26] . The specificity of downmodulation was confirmed by simultaneous measurement of mRNA and protein levels of a reference (HER-2). Assays for cell fusions revealed that syncytin antisense treatment significantly inhibited cancer-endothelial cell fusions. Additionally, we also found that a syncytin inhibitory peptide [24] inhibited cancer-endothelial cell fusions. These results provide definite evidence that syncytin is involved in mediating fusions between breast cancer cells and endothelial cells and suggest that spontaneous, syncytin-mediated fusions may occur in human breast cancer.
One can speculate that cancer-endothelial cell fusions occur in vivo when syncytin-producing cancer cells come into direct contact with ASCT-2-expressing endothelial cells, e.g. during extravasation. Depending upon the genetic make-up of the fusion partners, such fusions may either result in the activation of tumor suppressors contributed by the normal fusion partner [14] [15] [16] [17] [18] or may result in hybrids with more aggressive properties [4, [20] [21] [22] .
